A once-daily targeted tablet is reshaping expectations in one of oncology’s toughest diseases. New phase 3 data show the Daraxonrasib Pancreatic Cancer Pill nearly doubled median survival for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), compared with standard chemotherapy.
Clinicians typically identify pancreatic cancer late. Outcomes in metastatic disease have barely shifted for decades, especially after first-line chemotherapy. That is why the standing-room-only reaction at the American Society of Clinical Oncology (ASCO) meeting in Chicago was notable. ASCO’s chief medical officer, Julie Gralow, called the result a “grand slam”.
Daraxonrasib Pancreatic Cancer Pill Delivers Phase 3 Win
The RASolute 302 trial enrolled 500 patients across North America, Europe, and Asia. All had metastatic pancreatic adenocarcinoma that had progressed after prior therapy. The trial randomised patients to daraxonrasib or investigator’s choice chemotherapy.
Median overall survival was 13.2 months with daraxonrasib, versus 6.6 to 6.7 months with chemotherapy. Progression-free survival also improved to about 7.2 to 7.3 months, versus 3.5 to 3.6 months on chemotherapy.
Rachna Shroff, an ASCO gastrointestinal cancers expert who did not participate in the study, described the findings as “landscape-changing.”
What Daraxonrasib Pancreatic Cancer Pill Targets
Daraxonrasib is a RAS(ON) multi-selective inhibitor designed to shut down RAS signalling. This matters because more than 90% of pancreatic ductal adenocarcinomas carry activating KRAS mutations, most commonly RAS G12 variants. Earlier KRAS drugs tended to focus on single variants.
ASCO also highlighted a practical advantage. The data demonstrated a survival benefit in the overall study population, rather than just a narrow mutation subtype. That broad activity could simplify pathways in busy oncology services, where rapid treatment decisions are routine.
Safety Profile And Service Planning Implications
The trial results suggest fewer treatment stoppages than chemotherapy. In the NEJM report, treatment-related adverse events leading to discontinuation were 1.2% with daraxonrasib versus 11.2% with chemotherapy. Grade 3 or higher adverse events were also lower overall with daraxonrasib.
For health systems and funders, the near-term questions shift from “does it work?” to “how will it be used”? Second-line mPDAC is a high-cost, high-intensity setting. Any therapy that extends survival and is easier to tolerate can change utilisation patterns, including inpatient stays, supportive care needs, and infusion capacity.
The Daraxonrasib Pancreatic Cancer Pill is still investigational in many markets, and wider access will depend on regulatory review. In the US, regulators have already signalled urgency through an early-access pathway for eligible patients upon physician request.
Read the Original Article (May require a subscription)